Z45 Stock Overview
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Alvotech Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.45 |
| 52 Week High | US$17.20 |
| 52 Week Low | US$6.08 |
| Beta | -0.022 |
| 1 Month Change | 14.75% |
| 3 Month Change | -9.12% |
| 1 Year Change | 52.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| Z45 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.6% | -0.7% | 2.5% |
| 1Y | 52.6% | -21.2% | 5.4% |
Return vs Industry: Z45 exceeded the German Biotechs industry which returned -21.2% over the past year.
Return vs Market: Z45 exceeded the German Market which returned 5.4% over the past year.
Price Volatility
| Z45 volatility | |
|---|---|
| Z45 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Z45's share price has been volatile over the past 3 months.
Volatility Over Time: Z45's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 999 | Robert Wessman | www.alvotech.com |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Alvotech Fundamentals Summary
| Z45 fundamental statistics | |
|---|---|
| Market cap | €3.53b |
| Earnings (TTM) | -€512.12m |
| Revenue (TTM) | €86.68m |
40.0x
P/S Ratio-6.8x
P/E RatioIs Z45 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Z45 income statement (TTM) | |
|---|---|
| Revenue | US$93.38m |
| Cost of Revenue | US$160.86m |
| Gross Profit | -US$67.47m |
| Other Expenses | US$484.26m |
| Earnings | -US$551.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -1.97 |
| Gross Margin | -72.26% |
| Net Profit Margin | -590.83% |
| Debt/Equity Ratio | -103.0% |
How did Z45 perform over the long term?
See historical performance and comparison